Adial Pharmaceuticals, Inc. entered into an employment agreement with Tony Goodman
- Cash$5.9MCash up $2.1M vs the Dec 2024 quarter
- Operating burn, last quarter$6.4MBurn up $4.6M vs the Jun 2025 quarter
- Shares outstanding2.6M+201% from 873K on Aug 8, 2025, adjusted for the 1-for-25 reverse split by Mar 4, 2026
From the 10-Q/A 0001213900-26-111121 on EDGAR
Latest Adial Pharmaceuticals’ latest filing is a Form 4 from . Every Adial Pharmaceuticals filing is below, newest first.
Dilution Known so far: no new shares beyond today's 2.6M · shelf room about $2.2M · not yet read: warrants, converts, options, ATM; 1.3M registered for resale, likely already outstanding, not counted. Every source
Insiders No open-market insider buys or sells at Azora Therapeutics, Inc. (DE) in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders. Every trade
Coastlands Capital LP, insider filing for AZR
- Coastlands Capital LP owned 388,308 common shares.
- Series A Preferred Stock converted to common stock on Nov 2, 2026.
- Reporting persons no longer own more than 10% of common stock.
Cash runway and key numbers
Cash is not tagged in the latest report, so there is no runway estimate.
From the 10-Q/A 0001213900-26-111121 for the period ended Jun 30, 2026, as tagged in its XBRL. An estimate from reported figures, not a forecast or advice.
Every quarter as a table
| Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | |
|---|---|---|---|---|---|---|---|---|
| Cash | $5.2M | $3.8M | $2.4M | $5.9M | $4.6M | $5.9M | — | — |
| Quarterly burn | $1.7M | $1.5M | $1.6M | $1.7M | $1.8M | $1.3M | $1.6M | $6.4M |
| Shares outstanding | 6.4Mas of Nov 12 | 6.6Mas of Feb 28 | 7.9Mas of May 13 | 21.8Mas of Aug 8 | 24.0Mas of Nov 7 | 1.4Mas of Mar 4 | 2.1Mas of May 6 | 2.6Mas of Aug 12 |
| R&D | $1.0M | $731K | $747K | $732K | $521K | $619K | $433K | — |
All filings
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
Results, 8-Ks and key filings
8-KAdial PharmaceuticalsAZRLIVEEDGAR
No open-market insider buys or sells at Azora Therapeutics, Inc. (DE) in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders. Every AZR insider trade
Other filings
Schedule 13G/AAdial PharmaceuticalsAZRLIVEEDGAR Azora Therapeutics, Inc. corrects CIK error in filing
- Amended Schedule 13G filed on Nov 3, 2026
- Corrected CIK error from previous filing
- Coastlands Capital LP and affiliates signed the filing
Filed by Coastlands Capital LP
Shares registered for resale
Known so far: no new shares beyond today's 2.6M · shelf room about $2.2M · not yet read: warrants, converts, options, ATM.
1.3M registered for resale, already counted in today's shares where issued; all likely already outstanding.
- 5.0M shares registered for resale (200K after the 1-for-25 reverse split by Mar 4, 2026; 7.6% of today's 2.6M) under the S-1 of Dec 20, 2024, newest prospectus the 424B3 of Dec 31, 2024; likely already outstanding
- 2.4M shares registered for resale (94.8K after the 1-for-25 reverse split by Mar 4, 2026; 3.6% of today's 2.6M) under the S-3 of Apr 12, 2024, newest prospectus the 424B5 of May 2, 2025; likely already outstanding
- 4.3M shares registered for resale (174K after the 1-for-25 reverse split by Mar 4, 2026; 6.6% of today's 2.6M) under the S-1 of Nov 8, 2023, newest prospectus the 424B5 of May 2, 2025; likely already outstanding
- 6.7M shares registered for resale (269K after the 1-for-25 reverse split by Mar 4, 2026; 10.3% of today's 2.6M) under the S-3 of May 30, 2025, newest prospectus the 424B3 of Jun 10, 2025; likely already outstanding
- 13.8M shares registered for resale (553K after the 1-for-25 reverse split by Mar 4, 2026; 21.1% of today's 2.6M) under the S-3 of Dec 12, 2025, newest prospectus the 424B5 of Dec 19, 2025; likely already outstanding
Already in the Aug 12, 2026 share count: the shares sold in the 424B5 of Jun 18, 2025 (EDGAR).
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
0 open of 1 listing notice from 8-K item 3.01.
- Aug 21, 2026 8-K item 3.01 notice; rule and cure date not stated, see the filing
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for AZR since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Fails-to-deliver: 6,373 shares on Aug 31, 2026, per SEC data
Coming up
- Earnings, expected
- 10-Q, expected (deadline Nov 16)
Stated dates are as each filing on EDGAR gives them; an expected date is estimated from the company's past filing dates, the same estimate as the top of the page. Not investment advice.
Adial Pharmaceuticals shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Shares outstandingas of Aug 12, 2026 (10-Q/A filed Oct 21)2.6Mwarrants, notes and options not read yet, so fully diluted is not known
- Listing compliance8-K item 3.011 noticestatus not stated, see the filings
Insider activity
No open-market insider buys or sells at Azora Therapeutics, Inc. (DE) in the last 90 days; 5 filings reported awards, option exercises, tax withholding or new insiders.